Investor's Business Daily on MSN2d
Vir Biotechnology Catapults 58% On Promising Results In Cancer Treatment
Vir Biotechnology announced promising results Wednesday for a pair of cancer treatments, and Vir stock catapulted by double ...
Vir Biotechnology, Once a Hot Covid Stock, Finds New Path Forward in Cancer
Shares of the battered biotech Vir Biotechnology were up more than 70% on Wednesday, as the company reported its first ...
Vir Biotechnology: A Rocket Off Phase 1 Data... What Could Go Wrong?
Vir Biotechnology's recent share price rally is driven by their promising cancer program. Having shot to over a $1.5B market ...
Vir Biotechnology: Buy Rating Supported by Promising TCE Programs and Strategic Partnerships
H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Vir Biotechnology (VIR – Research Report) today and set a price target of ...
Vir Biotechnology Reports Positive Phase 2 Results, Shares Surge by 58%
Following the publication of encouraging results from Phase 2 studies for two investigational cancer treatments, Vir ...
Vir Biotechnology Stock Soars On Prostate Cancer Trial Data - Here's Why
Vir Biotechnology's Phase 1 trials reveal promising safety and efficacy for dual-masked T-cell engagers targeting HER2 and ...
Vir Biotechnology’s Early Promise in Clinical Trials Warrants Hold Rating Amid Uncertainties
Morgan Stanley analyst Michael Ulz maintained a Hold rating on Vir Biotechnology (VIR – Research Report) today and set a price target of ...
Vir Biotechnology Reports Promising Trial Results for Cancer Therapies
Vir Biotechnology ( (VIR) ) has issued an update. Vir Biotechnology announced promising Phase 1 trial results for its ...
bovnews1d
Vir Biotechnology Inc (VIR) Stock: Surpassing Expectations in the Market?
JP Morgan has recently reduced Vir Biotechnology Inc (VIR) stock to Neutral rating, as announced on January 29, 2024, according to Finviz. Earlier, on September 8, 2023, BofA Securities had reduced ...